Capstone Investment Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Capstone Investment Advisors's XBI Position: Q1 2026 in Review
Capstone Investment Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 16% in Q1 2026, buying an estimated $982K and bringing the position to 57,915 shares worth $7.4M. The position accounts for 0.01% of the portfolio, ranked #348.
Capstone Investment Advisors first reported a position in XBI in Q2 2021 and has held it in 14 quarters since. The position peaked at $9.87M in Q4 2021. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Capstone Investment Advisors held 57,915 shares of State Street SPDR S&P Biotech ETF worth $7.4M as of Q1 2026.
- Capstone Investment Advisors bought 7,864 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $982K.
- State Street SPDR S&P Biotech ETF made up 0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #348 holding.
- Capstone Investment Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and has held it in 14 quarters since.
- Capstone Investment Advisors's State Street SPDR S&P Biotech ETF position peaked at $9.87M in Q4 2021.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.